Cargando…
Development of Peptide Vaccines in Dengue
Dengue is one of the most important arboviral infections worldwide, infecting up to 390 million people and causing 25,000 deaths annually. Although a licensed dengue vaccine is available, it is not efficacious against dengue serotypes that infect people living in South East Asia, where dengue is an...
Autores principales: | Reginald, Kavita, Chan, Yanqi, Plebanski, Magdalena, Poh, Chit Laa |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Bentham Science Publishers
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6040172/ https://www.ncbi.nlm.nih.gov/pubmed/28914200 http://dx.doi.org/10.2174/1381612823666170913163904 |
Ejemplares similares
-
Enhancement of Tetravalent Immune Responses to Highly Conserved Epitopes of a Dengue Peptide Vaccine Conjugated to Polystyrene Nanoparticles
por: Chan, Yanqi, et al.
Publicado: (2020) -
Peptides as Therapeutic Agents for Dengue Virus
por: Chew, Miaw-Fang, et al.
Publicado: (2017) -
Development of Peptide-Based Vaccines for Cancer
por: Abd-Aziz, Noraini, et al.
Publicado: (2022) -
The Conserved Molecular Determinants of Virulence in Dengue Virus
por: Ahmad, Zuleeza, et al.
Publicado: (2019) -
The development of DNA vaccines against SARS-CoV-2
por: Khalid, Kanwal, et al.
Publicado: (2023)